Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany
Table 1
Patient demographics and baseline disease characteristics of OCEAN nAMD population and the three OCT examinations subgroups.
Total nAMD population, N = 3631
≤4 OCT subgroup, N = 466
5–7 OCT subgroup, N = 190
≥8 OCT subgroup, N = 497
Gender (n (%))
Male
1401 (38.6%)
193 (41.4%)
76 (40.0%)
191 (38.4%)
Female
2222 (61.2%)
273 (58.6%)
114 (60.0%)
306 (61.6%)
Missing
8 (0.2%)
0
0
0
Age (years)
n
3623
466
190
497
Mean (SD)
77.9 (8.1)
77.9 (8.9)
76.9 (8.9)
77.3 (8.2)
Pretreatment status
Treatment-naïve
2657 (73.2%)
370 (79.4%)
134 (70.5%)
364 (73.2%)
Pretreated with anti-VEGF
631 (17.4%)
62 (13.3%)
32 (16.8%)
109 (21.9%)
Possibly pretreated
343 (9.5%)
34 (7.3%)
24 (12.6%)
24 (4.8%)
Treatment delay (days)
n
3481
436
182
487
Mean (SD)
20.3 (19.4)
12.8 (13.0)
13.1 (11.3)
11.9 (10.5)
Median
15
10
13
10
Min–Max
0–90
0–79
0–47
0–57
BCVA of study eye at baseline
n
3601
466
190
497
Mean (SD) ETDRS letters
52.0 (21.2)
48.3 (25.2)
53.2 (21.1)
55.1 (17.9)
Number of injections
n
3631
466
190
497
Mean (SD)
5.7 (3.7)
3.0 (3.6)
7.1 (4.7)
8.4 (4.4)
Median
5
4
6
8
Min–Max
1–24
1–19
1–22
1–24
Pretreatment status was categorized as treatment-naïve (no previous intravitreal anti-VEGF documented and ≤90 days between diagnosis and first injection within OCEAN), pretreated (received anti-VEGF more than 3 months before study entry), and possibly pretreated (all remaining patients not meeting the other criteria). BCVA: best-corrected visual acuity; ETDRS: Early Treatment for Diabetic Retinopathy Study; Max: maximum; Min: minimum; nAMD: neovascular age-related macular degeneration; OCT: optical coherence tomography; SD: standard deviation; VEGF: vascular endothelial growth factor.
